Medicine guide

Tremelimumab AstraZeneca

·

  • Prescription status not stated
  • Cancer treatments and immune-system medicines
Active substance
Tremelimumab
Made by
AstraZeneca AB

Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.

What it is for

  • Tremelimumab AstraZeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.

From the official label · 2026-09-30 · European Medicines Agency

Same active substance, strength and form in other countries

Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.

Medicine passport: one printable page to show a pharmacist abroad

United StatesNo exact match for this strength and form

SpainNo exact match for this strength and form

CanadaNo exact match for this strength and form

NetherlandsNo exact match for this strength and form

SwitzerlandNo exact match for this strength and form

Details

Made byAstraZeneca AB
Active substanceTremelimumab
Used inCancer treatments and immune-system medicines
ClassificationL01FX20 · Cancer treatments and immune-system medicines
Additional monitoring ▼Yes — under additional monitoring (black triangle). Report suspected side effects.
Authorised on2023-02-20
Last updated by the regulator2024-08-22
EMA product numberEMEA/H/C/004650

Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician

Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).

Same active substance

These contain the same substance. That does not mean one can replace another — ask a pharmacist.